About The Author

I am a pharmacologist and senior lecturer at the University of Sheffield (England, UK). The focus of my research is the development of drugs for inflammation and cancer.

Besides science, I am involved in business activities related to my research and my other passions include cycling touring, playing the piano and writing.

Another Feather In The Cap Of The Breast Cancer Oncogene IKKε

There has been considerable progress in the treatment of breast cancer. Advances in diagnosis, surgery, radiotherapy, and targeted chemotherapy have transformed the lives of many breast cancer sufferers. However, these benefits have certainly not been universally shared. Breast cancer recurrence and the complications associated with the spread of tumor cells to other organs still remain

A Cautionary Tale About Therapeutic Manipulation Of Bone Formation

In recent decades, there has been a significant increase in clinical efforts to develop bone anabolic agents that enhance bone regeneration by stimulating the activity of bone-forming cells, the osteoblasts. The therapeutic applications of many of bone anabolics available today including the parathyroid hormone-related protein (Tymlos®, Radius), the anti-Sclerostin antibody (Romosozumab®, Amgen), and Strontium Ranelate

The Ebb And Flow Of Therapeutic Targeting Of NFκB In Cancer

Chronic inflammation increases the risk of cancer, and anti-inflammatory drugs can have significant benefits for patients in terms of quality of life – including alleviating pain and in some cases improving survival. A growing body of evidence from preclinical models suggests that drugs that selectively target and inhibit the function of “bottleneck” proteins, those activated by

TRAFficking Of Breast Cancer Cells To Bone

Metastasis of cancer cells to bone is common in patients suffering from advanced stages of cancers that originate in distant organs such as breast, prostate, and lungs. Once in the skeleton, cancer cells acquire “bony” characteristics that enable them to influence and disrupt the function of bone cells such as osteoclasts – the bone cells

The Dilemma Of Targeting NFκB For The Treatment Of Secondary Cancer In Bone

The skeleton is a common site for metastatic cancer cells originated in distant organs. Skeletal-related events such as excessive bone damage and bone pain are often diagnosed in cancer patients suffering from bone metastasis and those undergoing cancer treatments such as chemotherapy. Once in bone, metastatic cancer cells acquire “bony” characteristics that enable these foreign

Nail Testing Detects Bone Loss In Mice: Implications For Osteoporosis And Beyond

Ageing is associated with many degenerative processes, including the gradual deterioration of the skeleton. Osteoporosis (brittle bone) is a common bone disease characterized by bone weakness and an increased risk of fractures that increases dramatically in incidence with age. The risk of osteoporosis and related fractures is determined by a balance between levels of peak